GlassScriptPhysician profile
Marta P Suarez-Rivera
NPI 1023271061
$6,980.96
in general payments reported to CMS, 2019-2025
21 companies · $5,034 in 2025
The $5,034 reported for 2025 was more than what 87% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $25.22 · 2021: $129 · 2022: $375 · 2023: $482 · 2024: $568 · 2025: $5,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,934 · Travel and Lodging: $1,321 · Education: $28.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,934.24 |
| Travel and Lodging | $1,321.04 |
| Education | $28.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4,442.00 | 2025 | Filspari |
| Alexion Pharmaceuticals, INC. | $497.68 | 2023-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $352.89 | 2022-2025 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $259.63 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $178.99 | 2020-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $144.32 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $125.24 | 2024 | |
| Novo Nordisk INC | $117.87 | 2025 | Rivfloza |
| Calliditas Therapeutics US INC. | $107.95 | 2025 | Tarpeyo |
| Kyowa Kirin, INC. | $102.20 | 2023 | |
| Vifor Pharma, INC. | $99.80 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $98.94 | 2022-2023 | Imcivree |
| Apellis Pharmaceuticals, INC. | $86.18 | 2025 | |
| Bard Peripheral Vascular, INC. | $81.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.74 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $74.68 | 2019 | |
| Amgen INC. | $48.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.75 | 2021 | |
| Medtronic, INC. | $34.71 | 2021-2023 | Carpediem |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Suarez-Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.